rethinkTHC Search
Menu
Study breakdown

What Blood Tests Reveal About Adolescent Cannabinoid Hyperemesis Syndrome

Pilot StudyPreliminary evidence
The takeaway

In a pilot study of 10 adolescent ER patients with CHS, all had cannabis use disorder, reported withdrawal symptoms, and showed specific cannabinoid metabolite and mineral profiles that may help diagnose and manage the condition.

Emergency physicians diagnosing CHS, pediatric gastroenterologists, and researchers developing CHS biomarkers.

What the researchers found

This pilot study screened 869 adolescent emergency department patients to identify 10 with cyclic vomiting onset after chronic cannabis use—a ratio that illustrates both how common the screening population is and how specifically they identified CHS cases.

All 10 participants had cannabis use disorder (9) or hazardous cannabis use (1) by validated assessment. All reported withdrawal symptoms when trying to stop cannabis—confirming that CHS occurs in the context of physiological dependence, not casual use.

The study's innovation was comparing blood profiles during symptomatic episodes versus asymptomatic follow-up visits. Cannabinoid metabolite levels and essential mineral and B vitamin levels were quantified at both timepoints. This within-person comparison is valuable because it controls for individual differences.

The findings about minerals and B vitamins are particularly relevant given RTHC-00164's case of CHS-induced Wernicke's encephalopathy from thiamine deficiency. If specific nutrient deficiencies are part of the CHS picture—not just a consequence of prolonged vomiting—they could become both diagnostic markers and treatment targets.

Why it matters

CHS diagnosis is currently clinical—there's no blood test. If specific cannabinoid metabolite patterns or mineral changes reliably distinguish CHS from other causes of cyclic vomiting, that could dramatically improve emergency department diagnosis. It would also connect to RTHC-00205's finding that aprepitant rapidly resolved CHS when standard treatments failed—better diagnosis could lead to faster appropriate treatment.

The numbers in context

869 adolescents screened; 10 enrolled with CHS. 9/10 had cannabis use disorder, 1 hazardous use. All reported withdrawal symptoms. Blood drawn at symptomatic and asymptomatic visits for cannabinoid metabolites, minerals, and B vitamins.

How the study worked

Pilot prospective observational cohort study. Screened 869 adolescent ED patients (ages 14–21); enrolled 10 with symptomatic cyclic vomiting after chronic cannabis use. Assessed at symptomatic presentation and asymptomatic follow-up. Cannabis use patterns: validated questionnaires. Blood profiles: cannabinoid metabolites, essential minerals, and B vitamins at both timepoints.

Who was studied

N=10 adolescents aged 14-21, 50% female, from a pediatric emergency department

What this study cannot tell us

Extremely small sample (10 patients). Pilot study—powered for feasibility, not for drawing firm conclusions about biomarkers. Single ED site. The within-person comparison is strong but individual variation is high. Not all adolescents with CHS may present to the ED. The 869:10 screening ratio suggests high specificity of the inclusion criteria but may miss milder presentations.

How to read the evidence

Small pilot study designed for feasibility—generates hypotheses about biomarkers but is too small to validate them.

When this study was published

Published in 2026, contributing to the growing focus on CHS in adolescents.

The bigger picture

This pilot builds the evidence base for understanding CHS pathophysiology. RTHC-00164 showed CHS can cause Wernicke's encephalopathy via thiamine deficiency. RTHC-00205 showed aprepitant can rescue treatment-resistant CHS. This study adds the biomarker dimension—potentially enabling earlier diagnosis and more targeted treatment. The universal cannabis use disorder finding also confirms that CHS is a condition of dependence, not of occasional use.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

  • Can the cannabinoid metabolite profiles distinguish CHS from cyclic vomiting syndrome unrelated to cannabis? Would mineral supplementation during CHS episodes prevent complications like Wernicke's encephalopathy? Is cannabis use disorder severity correlated with CHS episode severity?

Read the original research

Cannabis Use Patterns and Blood Profiles in Adolescent Cannabinoid Hyperemesis Syndrome.

Pediatric emergency care, 42(1), e13-e19

Pediatric Emergency Care is a well-regarded journal focusing on emergency medicine for children.

Citation

Bloom, Joshua; Beaudoin, Francesca L; Lin, Timmy R; Gaipo, Ashley; Ortega, Carolyn; Wightman, Rachel S. (2026). Cannabis Use Patterns and Blood Profiles in Adolescent Cannabinoid Hyperemesis Syndrome.. Pediatric emergency care, 42(1), e13-e19. https://doi.org/10.1097/PEC.0000000000003495

Explore the wider topic